{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:35Z","timestamp":1790821955608,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":174,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ymthe.2017.12.009","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T03:22:39Z","timestamp":1513221759000},"page":"496-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice"],"prefix":"10.1016","volume":"26","author":[{"given":"Stuart","family":"Bunting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lening","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Bullens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Mahimkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Sandza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Handyside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong-Ryoul","family":"Sihn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Galicia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Tsuruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Colosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinong","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Vehar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrie","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.12.009_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia: a narrative review","volume":"7","author":"Franchini","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2017.12.009_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0950-3536(11)80025-9","article-title":"Epidemiology of coagulation disorders","volume":"5","author":"Nathwani","year":"1992","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.ymthe.2017.12.009_bib3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.12.009_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2516.2009.02127.x","article-title":"A study of variations in the reported haemophilia A prevalence around the world","volume":"16","author":"Stonebraker","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2017.12.009_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JBM.S42669","article-title":"Emerging and future therapies for hemophilia","volume":"6","author":"Carr","year":"2015","journal-title":"J.\u00a0Blood Med."},{"key":"10.1016\/j.ymthe.2017.12.009_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2017.12.009_bib7","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.12.009_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.12.009_bib12","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.12.009_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V128.22.3.3","article-title":"Adeno-associated virus\u00a0mediated gene transfer for hemophilia B achieves sustained mean factor IX activity levels of > 30% without immunosuppression","volume":"128","author":"Lindsey","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rth2.12026","volume":"1","author":"George","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2017.12.009_bib15","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood.V128.22.2314.2314","article-title":"Interim results from a dose escalating study of AMT-060 (AAV5-hFIX) gene transfer in adult patients with severe hemophilia B","volume":"128","author":"Leebeek","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib16","first-page":"1","article-title":"Updated results from a dose escalation study in adults with severe or moderate-severe hemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy: up to 1.5 years follow-up","volume":"1","author":"Miesbach","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2017.12.009_bib17","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood.V126.23.2040.2040","article-title":"Adeno-associated virus 8 (AAV8) vector genome biodistribution into body fluids following single intravenous administration of BAX 335 gene therapy for hemophilia B","volume":"126","author":"Boyan Litchev","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/ajh.24543","article-title":"2017 clinical trials update: innovations in hemophilia therapy","volume":"91","author":"Hartmann","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2017.12.009_bib19","first-page":"1","article-title":"An analysis of bleeding rates and factor IX consumption in the Phase I\/II BAX 335 gene therapy trial in subjects with hemophilia B","volume":"1","author":"Chapin","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2017.12.009_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.seminhematol.2015.10.002","article-title":"Gene therapy for hemophilia: past, present and future","volume":"53","author":"George","year":"2016","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymthe.2017.12.009_bib21","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1093\/hmg\/ddv475","article-title":"Adeno-associated viral vectors for the treatment of hemophilia","volume":"25","author":"High","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2017.12.009_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.13543","article-title":"Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A","volume":"15","author":"Nguyen","year":"2016","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2017.12.009_bib23","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1073\/pnas.96.22.12725","article-title":"Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein","volume":"96","author":"Burton","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2017.12.009_bib24","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib25","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.12.009_bib26","doi-asserted-by":"crossref","first-page":"15049","DOI":"10.1038\/mtm.2015.49","article-title":"Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome","volume":"3","author":"Ayuso","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.12.009_bib27","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2017.12.009_bib28","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.12.009_bib29","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.12.009_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ymgme.2011.06.002","article-title":"Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates","volume":"104","author":"Bell","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2017.12.009_bib31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ymthe.2005.05.016","article-title":"Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector","volume":"12","author":"Conlon","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ymthe.2004.12.022","article-title":"Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models","volume":"11","author":"Davidoff","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib33","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to detect pre-existing immunity to AAV gene therapy","author":"Falese","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib35","doi-asserted-by":"crossref","first-page":"16034","DOI":"10.1038\/mtm.2016.34","article-title":"Clinical development of gene therapy: results and lessons from recent successes","volume":"3","author":"Kumar","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.12.009_bib36","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hae.12550","article-title":"Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study","volume":"21","author":"Morfini","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2017.12.009_bib38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors","volume":"22","author":"Wang","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib39","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ymthe.2017.12.009_bib40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.12.009_bib41","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib42","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/gt.2014.47","article-title":"Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors","volume":"21","author":"Liu","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/gt.2015.109","article-title":"Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure","volume":"23","author":"Greenberg","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2006.17.440","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors","volume":"17","author":"Halbert","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib46","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1089\/hum.2009.031","article-title":"Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders","volume":"20","author":"Pa\u00f1eda","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.12.009_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013factor VIII gene transfer in severe hemophilia A","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.12.009_bib48","first-page":"151","article-title":"Interim results of an open-label, phase 1\/2 study of BMN 270, an AAV5-FVIII gene transfer in severe hemophilia A","volume":"22","author":"Pasi","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2017.12.009_bib49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2017.12.009_bib51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(92)90029-C","article-title":"RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement","volume":"68","author":"Shinkai","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2017.12.009_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2002-09-2889","article-title":"Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway","volume":"102","author":"Davidoff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.12.009_bib54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2516.2011.02608.x","article-title":"Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice","volume":"18","author":"Elm","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2017.12.009_bib55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2017.12.009_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-385114-7.00004-0","article-title":"Measuring ER stress and the unfolded protein response using mammalian tissue culture system","volume":"490","author":"Oslowski","year":"2011","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ymthe.2017.12.009_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.taap.2014.12.019","article-title":"Tunicamycin-induced unfolded protein response in the developing mouse brain","volume":"283","author":"Wang","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617306068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617306068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T04:20:30Z","timestamp":1603513230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617306068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1525001617306068"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 BioMarin Pharmaceutical Inc.","name":"copyright","label":"Copyright"}]}}